Cornerstone Investment Partners LLC Acquires New Stake in ChromaDex Co. (NASDAQ:CDXC)

Cornerstone Investment Partners LLC bought a new position in ChromaDex Co. (NASDAQ:CDXC) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 26,604 shares of the company’s stock, valued at approximately $141,000.

A number of other institutional investors have also recently modified their holdings of CDXC. Barclays PLC boosted its stake in ChromaDex by 322.1% in the 3rd quarter. Barclays PLC now owns 70,072 shares of the company’s stock worth $256,000 after purchasing an additional 53,472 shares in the last quarter. Sargent Investment Group LLC purchased a new position in ChromaDex in the fourth quarter worth about $263,000. FMR LLC purchased a new position in ChromaDex in the third quarter worth about $55,000. JPMorgan Chase & Co. grew its holdings in shares of ChromaDex by 11.1% during the third quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company’s stock valued at $1,211,000 after buying an additional 33,150 shares during the last quarter. Finally, State Street Corp increased its position in shares of ChromaDex by 11.3% during the third quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after acquiring an additional 62,692 shares in the last quarter. 15.41% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the transaction, the director now owns 244,179 shares of the company’s stock, valued at approximately $1,511,468.01. This represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.64% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. StockNews.com raised ChromaDex from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 24th. Roth Mkm upped their price target on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, November 6th.

ChromaDex Stock Up 1.8 %

CDXC opened at $5.60 on Wednesday. The stock has a market capitalization of $427.74 million, a price-to-earnings ratio of 560.56 and a beta of 2.21. The firm has a 50 day moving average price of $5.62 and a 200-day moving average price of $5.11. ChromaDex Co. has a twelve month low of $1.57 and a twelve month high of $7.97.

ChromaDex Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.